DNA‐Scaffolded Bispecific Antibodies Enhance Mesenchymal Stromal Cell Therapy for Inflammatory Bowel Disease
Advanced Materials · 2026-01 · 38 (4)
DOI: 10.1002/adma.202511854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 14.10.2025. Verfasst von Xi Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 511442, P. R. China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Inflammatory Bowel Diseases, Mesenchymal Stem Cells, DNA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Mesenchymal stromal cells (MSCs) are considered a promising cell‐based therapy for inflammatory bowel disease (IBD), due to their potent immunomodulatory properties and robust regenerative potential. However, their therapeutic efficacy against IBD is hindered by poor homing capacity and excessive leukocyte infiltration at inflamed colonic sites. In this study, MSCs with a Y‐shaped bispecific antibody (YMV) assembled via DNA nanotechnology, which integrates anti‐vascular cell adhesion molecule‐1 (anti‐VCAM‐1) and anti‐mucosal addressing cell adhesion molecules‐1 (anti‐MAdCAM‐1) antibodies are engineered, to enhance targeted delivery and inhibit leukocyte recruitment. YMV‐modified MSCs show an approximately threefold enhancement in adhesion efficiency compared with native MSCs. Notably, they effectively compete for MAdCAM‐1 binding sites and significantly suppress leukocyte adhesion. In a mouse model of IBD, YMV‐MSCs demonstrate enhanced homing to the colon, promote mucosal repair, reduce leukocyte infiltration, and attenuate local inflammation. This DNA‐mediated bispecific antibody modification strategy improves MSCs targeting and exerts anti‐inflammatory effects by blocking leukocyte recruitment, offering a promising platform for MSC‐based therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 511442, P. R. China.
- Department of Ophthalmology, Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, P. R. China.
- Department of General Surgery (Colorectal Surgery), Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, Biomedical Innovation Center, The Sixth Affiliate…
- National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, 510006, P. R. China.
- Guangdong Provincial Key Laboratory of Biomedical Engineering, South China University of Technology, Guangzhou, 510006, P. R. China.
ORCID-Profile: Peng Shi
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Science and Technology Program of Guangzhou
- National Key Research and Development Program of China
Zitieren
APA
Liu, X., Ye, T., Yang, L., Wu, J., Fu, Q., Peng, X., Luo, J., Huang, X., Zhang, D., & Shi, P. (2026). DNA‐Scaffolded Bispecific Antibodies Enhance Mesenchymal Stromal Cell Therapy for Inflammatory Bowel Disease. Advanced Materials, 38(4). https://doi.org/10.1002/adma.202511854
Vancouver
Liu X, Ye T, Yang L, Wu J, Fu Q, Peng X, et al. DNA‐Scaffolded Bispecific Antibodies Enhance Mesenchymal Stromal Cell Therapy for Inflammatory Bowel Disease. Advanced Materials. 2026;38(4). doi:10.1002/adma.202511854
BibTeX
@article{Liu2026,
author = {Liu, Xi and Ye, Tenghui and Yang, Leyi and Wu, Jiamin and Fu, Qin and Peng, Xi and Luo, Jiajia and Huang, Xiaobo and Zhang, Di and Shi, Peng},
title = {DNA‐Scaffolded Bispecific Antibodies Enhance Mesenchymal Stromal Cell Therapy for Inflammatory Bowel Disease},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {4},
doi = {10.1002/adma.202511854}
}
EUVIMED